Doxorubicin cardiotoxicity in children: Reduced incidence of cardiac dysfunction associated with continuous-infusion schedules

  • Authors:
    • Su G. Berrak
    • Michael S. Ewer
    • Norman Jaffe
    • Peggy Pearson
    • Hubert Ried
    • Hallie A. Zietz
    • Robert S. Benjamin
  • View Affiliations

  • Published online on: May 1, 2001     https://doi.org/10.3892/or.8.3.611
  • Pages: 611-614
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We retrospectively reviewed the medical records of 97 children (59 boys and 38 girls) with a median age of 13±4 years who had been treated with continuous infusion of doxorubicin at a dosage of 60 mg/m2 over 24 h (61 patients) or at a dosage of 75 mg/m2 over 72 h (36 patients). The drug was administered every 3 weeks. The cardiac status of patients was evaluated as a baseline and every 6 months during, and following therapy (median, 30.5 months). The evaluations included M-mode and two-dimensional echocardiography. Congestive heart failure developed in only one patient in this series, an 8-year-old girl who ultimately died of her cardiac complication. This incidence of doxorubicin-induced cardiotoxicity was compared with that seen in a control group of pediatric patients previously treated with doxorubicin at similar dosages but with a rapid infusion. The result compared favorably to the 13% incidence of cardiotoxicity (p=0.03) and 7% mortality (p<0.01) in the control group. No changes in the levels of tumor response were noted in children treated by continuous infusion when compared with historical controls. Continuous-infusion schedules of doxorubicin thus result in fewer incidences of cardiotoxicity in children and should be considered for wider application in pediatric cancer patients receiving doxorubicin.

Related Articles

Journal Cover

May-June 2001
Volume 8 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Berrak SG, Ewer MS, Jaffe N, Pearson P, Ried H, Zietz HA and Benjamin RS: Doxorubicin cardiotoxicity in children: Reduced incidence of cardiac dysfunction associated with continuous-infusion schedules. Oncol Rep 8: 611-614, 2001
APA
Berrak, S.G., Ewer, M.S., Jaffe, N., Pearson, P., Ried, H., Zietz, H.A., & Benjamin, R.S. (2001). Doxorubicin cardiotoxicity in children: Reduced incidence of cardiac dysfunction associated with continuous-infusion schedules. Oncology Reports, 8, 611-614. https://doi.org/10.3892/or.8.3.611
MLA
Berrak, S. G., Ewer, M. S., Jaffe, N., Pearson, P., Ried, H., Zietz, H. A., Benjamin, R. S."Doxorubicin cardiotoxicity in children: Reduced incidence of cardiac dysfunction associated with continuous-infusion schedules". Oncology Reports 8.3 (2001): 611-614.
Chicago
Berrak, S. G., Ewer, M. S., Jaffe, N., Pearson, P., Ried, H., Zietz, H. A., Benjamin, R. S."Doxorubicin cardiotoxicity in children: Reduced incidence of cardiac dysfunction associated with continuous-infusion schedules". Oncology Reports 8, no. 3 (2001): 611-614. https://doi.org/10.3892/or.8.3.611